molecules of the month


oral, covalent MK2 inhibitor

Ph. II candidate in ankylosing spondylitis

from previously disclosed MK2 inhibitor and SBDD

Transl Res

Bristol Myers Squibb, Princeton, NJ

CC-99677 Chemical Structure oral, covalent MK2 inhibitor - Bristol Myers Squibb, Princeton, NJ
4 mins read

Context. CC-99677 (BMS) is an oral, covalent MAPK–activated protein kinase-2 (MK2) inhibitor being developed for autoimmune diseases. Although p38 is the most heralded member of the p38-MAPK signaling pathway, one that mediates the release of pro-inflammatory cytokines and is implicated in several inflammatory diseases, attempts to directly inhibit the kinase have been largely unsuccessful. Notably, these agents have been associated with a lack of sustained efficacy (tachyphylaxis), potentially stemming from their inhibition of other key proteins involved in feedback regulation of the signaling pathway. Consequently, targeting MK2, a downstream target of p38, is hypothesized as a strategy to circumvent this compensatory feedback mechanism. CC-99677 was found by BMS scientists to mediate a cytokine inhibitory profile different from that of previously…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: